vaccines with improved effectivenessand theirtimely availabilit
the product, should facilitate continued evolution of influenz
this technology, together with the molecular characterisation o
an ‘innovativedrug’ designationfromHealthCanada49.Theuseo
Committee for Medicinal Products for Human Use (CHMP)48 an
tion from FDA, a ‘new active substance’ designation from EM
these unique features, RIV4 received ‘product exclusivity’ protec
certain aspects of vaccine safety and efficacy (Fig. 2). Based o
materialandthemanufacturingprocess,whichhaveanimpacto
terms of specific structural features, the nature of the sourc
containedinRIV4differs fromthatexpressedinother systemsi
various groups in both pre-clinical models and humans. The rH
Insect cell-derived rHA (RIV4) has been studied extensively b